These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1043 related articles for article (PubMed ID: 24785575)

  • 1. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
    Sun W; Ni R; Zhang X; Li LC; Mao S
    Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
    Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative.
    Xu D; Ni R; Sun W; Li LC; Mao S
    Drug Dev Ind Pharm; 2015 Apr; 41(4):552-9. PubMed ID: 24495272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole.
    Kumar S; Shen J; Burgess DJ
    J Control Release; 2014 Oct; 192():95-102. PubMed ID: 25009979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs.
    De Smet L; Saerens L; De Beer T; Carleer R; Adriaensens P; Van Bocxlaer J; Vervaet C; Remon JP
    Eur J Pharm Biopharm; 2014 May; 87(1):107-13. PubMed ID: 24388913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
    Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
    Mou D; Chen H; Wan J; Xu H; Yang X
    Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole.
    Kumar S; Jog R; Shen J; Zolnik B; Sadrieh N; Burgess DJ
    J Pharm Sci; 2015 Sep; 104(9):3018-28. PubMed ID: 25195539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
    Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z
    Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption.
    Sarnes A; Kovalainen M; Häkkinen MR; Laaksonen T; Laru J; Kiesvaara J; Ilkka J; Oksala O; Rönkkö S; Järvinen K; Hirvonen J; Peltonen L
    J Control Release; 2014 Apr; 180():109-16. PubMed ID: 24566254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
    Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets.
    Salazar J; Müller RH; Möschwitzer JP
    Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and drying of miconazole and itraconazole nanosuspensions.
    Cerdeira AM; Mazzotti M; Gander B
    Int J Pharm; 2013 Feb; 443(1-2):209-20. PubMed ID: 23291552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability.
    Fadke J; Desai J; Thakkar H
    AAPS PharmSciTech; 2015 Dec; 16(6):1434-44. PubMed ID: 25991065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of spray granulation for conversion of a nanosuspension into a dry powder form.
    Bose S; Schenck D; Ghosh I; Hollywood A; Maulit E; Ruegger C
    Eur J Pharm Sci; 2012 Aug; 47(1):35-43. PubMed ID: 22565066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of directly compressible powders via co-spray drying.
    Gonnissen Y; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2007 Aug; 67(1):220-6. PubMed ID: 17317123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation parameters of crystalline nanosuspensions on spray drying processing: a DoE approach.
    Kumar S; Xu X; Gokhale R; Burgess DJ
    Int J Pharm; 2014 Apr; 464(1-2):34-45. PubMed ID: 24447788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New nano-matrix oral formulation of nanoprecipitated cyclosporine A prepared with multi-inlet vortex mixer.
    Suzuki H; Hamao S; Seto Y; Sato H; Wong J; Prud'homme RK; Chan HK; Onoue S
    Int J Pharm; 2017 Jan; 516(1-2):116-119. PubMed ID: 27845213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanonized itraconazole powders for extemporary oral suspensions: Role of formulation components studied by a mixture design.
    Foglio Bonda A; Rinaldi M; Segale L; Palugan L; Cerea M; Vecchio C; Pattarino F
    Eur J Pharm Sci; 2016 Feb; 83():175-83. PubMed ID: 26742430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.